Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Large clinical trials involving patients with type 2 diabetes have shown that inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of hospitalization for heart failure. Most patients in these trials did not have heart failure at baseline, so the benefit of treatment with an SGLT2…

Leave a Reply

Your email address will not be published. Required fields are marked *